4//SEC Filing
Kaye Randall 4
Accession 0000950170-24-106949
CIK 0001832168other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 7:36 PM ET
Size
14.3 KB
Accession
0000950170-24-106949
Insider Transaction Report
Form 4
Kaye Randall
CMO
Transactions
- Exercise/Conversion
Common Stock
2024-09-16$4.35/sh+16,666$72,497→ 34,586 total - Sale
Common Stock
2024-09-16$34.04/sh−1,900$64,668→ 17,920 total - Sale
Common Stock
2024-09-16$31.81/sh−4,200$133,622→ 21,020 total - Sale
Common Stock
2024-09-16$33.12/sh−1,200$39,750→ 19,820 total - Sale
Common Stock
2024-09-16$30.89/sh−9,366$289,278→ 25,220 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-09-16−16,666→ 112,967 totalExercise: $4.35Exp: 2033-02-08→ Common Stock (16,666 underlying)
Footnotes (7)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
- [F2]The amount reported includes the 17,920 restricted stock units (RSUs) that were granted on February 8, 2024, and reported in a Form 4 filed on February 9, 2024. The RSUs will vest in four equal annual installments commencing on February 8, 2025, and the shares underlying the RSUs will be issued upon vesting and release of the RSUs.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.54 to $31.52, inclusive. The reporting person undertakes to provide Longboard Pharmaceuticals, Inc., any security holder of Longboard Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5 and 6 to this Form 4.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.56 to $32.40, inclusive.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.80 to $33.68, inclusive.
- [F6]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.86 to $34.33, inclusive.
- [F7]The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 9, 2023.
Documents
Issuer
Longboard Pharmaceuticals, Inc.
CIK 0001832168
Entity typeother
Related Parties
1- filerCIK 0001350416
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 7:36 PM ET
- Size
- 14.3 KB